Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
19.23
-0.48 (-2.44%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $19.65M in the twelve months ending June 30, 2024, down -92.33% year-over-year. In the fiscal year ending September 30, 2023, Arrowhead Pharmaceuticals had annual revenue of $240.74M, down -1.03%.
Revenue (ttm)
$19.65M
Revenue Growth
-92.33%
P/S Ratio
113.04
Revenue / Employee
$37,425
Employees
525
Market Cap
2.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | 168.80M | 152.65M | 945.67% |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
| Sep 30, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardent Health Partners | 5.63B |
| ACADIA Pharmaceuticals | 890.53M |
| Amphastar Pharmaceuticals | 712.89M |
| Inari Medical | 574.50M |
| Catalyst Pharmaceuticals | 434.48M |
| Twist Bioscience | 295.21M |
| IDEAYA Biosciences | 11.96M |
| Geron | 1.37M |
ARWR News
- 17 days ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug - Investopedia
- 2 months ago - Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript) - Seeking Alpha
- 2 months ago - Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies - Business Wire